|
Delayed
Japan Exchange
01:30:00 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 2,696.00 JPY | -5.54% |
|
-1.61% | +2.59% |
| 10-05 | ROHTO Pharmaceutical Co., Ltd. Revises Earnings Guidance for the Fiscal Year 2031 | CI |
| 10-05 | ROHTO Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2026, 2029 and 2032 | CI |
Company Valuation: Rohto Pharmaceutical Co.,Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 421,488 | 631,946 | 676,888 | 505,369 | 544,009 | 609,200 | - | - |
| Change | - | 49.93% | 7.11% | -25.34% | 7.65% | 11.98% | - | - |
| Enterprise Value (EV) 1 | 370,080 | 563,688 | 598,172 | 453,061 | 484,807 | 554,629 | 539,726 | 522,660 |
| Change | - | 52.31% | 6.12% | -24.26% | 7.01% | 14.4% | -2.69% | -3.16% |
| P/E | 20.1x | 24x | 21.9x | 16.4x | 15.9x | 16.6x | 15.7x | 15x |
| PBR | 2.37x | 3.02x | 2.75x | 1.95x | 1.8x | 1.92x | 1.78x | 1.65x |
| PEG | - | 0.9x | 1.3x | 44.48x | 1.4x | 2.42x | 2.66x | 3.3x |
| Capitalization / Revenue | 2.11x | 2.65x | 2.5x | 1.64x | 1.58x | 1.63x | 1.56x | 1.51x |
| EV / Revenue | 1.85x | 2.36x | 2.21x | 1.47x | 1.41x | 1.49x | 1.38x | 1.3x |
| EV / EBITDA | 10x | 13.5x | 12.3x | 8.7x | 8.29x | 8.72x | 8.05x | 7.44x |
| EV / EBIT | 12.6x | 16.6x | 14.9x | 11.6x | 11.8x | 12x | 10.8x | 9.91x |
| EV / FCF | 34.1x | 31.8x | 33.4x | 20.7x | 27.1x | 21x | 15.2x | 13.7x |
| FCF Yield | 2.93% | 3.15% | 3% | 4.82% | 3.69% | 4.76% | 6.56% | 7.32% |
| Dividend per Share 2 | 18 | 22 | 27 | 36 | 46 | 50.38 | 54.34 | 58.41 |
| Rate of return | 0.97% | 0.79% | 0.91% | 1.61% | 1.91% | 1.87% | 2.02% | 2.17% |
| EPS 2 | 92.13 | 115.6 | 135.6 | 136.1 | 151.6 | 162 | 171.5 | 179.3 |
| Distribution rate | 19.5% | 19% | 19.9% | 26.4% | 30.4% | 31.1% | 31.7% | 32.6% |
| Net sales 1 | 199,646 | 238,664 | 270,840 | 308,625 | 343,725 | 373,481 | 391,179 | 403,014 |
| EBITDA 1 | 37,022 | 41,760 | 48,735 | 52,082 | 58,496 | 63,623 | 67,026 | 70,282 |
| EBIT 1 | 29,349 | 33,959 | 40,048 | 38,939 | 41,118 | 46,327 | 49,830 | 52,738 |
| Net income 1 | 21,018 | 26,377 | 30,936 | 31,006 | 34,247 | 36,553 | 38,705 | 40,422 |
| Net Debt 1 | -51,408 | -68,258 | -78,716 | -52,308 | -59,202 | -54,571 | -69,474 | -86,539 |
| Reference price 2 | 1,847.50 | 2,770.00 | 2,967.00 | 2,236.50 | 2,407.50 | 2,696.00 | 2,696.00 | 2,696.00 |
| Nbr of stocks (in thousands) | 228,140 | 228,139 | 228,139 | 225,964 | 225,964 | 225,964 | - | - |
| Announcement Date | 5/12/22 | 5/12/23 | 5/13/24 | 5/13/25 | 5/13/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 16.64x | 1.49x | 8.72x | 1.87% | 3.85B | |
| 39.62x | 13.42x | 28.51x | 0.5% | 1,206B | |
| 40.43x | 6.79x | 19.09x | 1.93% | 665B | |
| 37.52x | 8.51x | 17.57x | 2.38% | 515B | |
| 20.98x | 5.12x | 12.74x | 2.57% | 381B | |
| 97.18x | 5.94x | 25.33x | 2.32% | 362B | |
| 23.18x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.46x | 4.89x | 13.77x | 1.79% | 289B | |
| 23.75x | 7.3x | 13.55x | 2.19% | 249B | |
| -39.18x | 7.28x | 45.82x | 1.98% | 207B | |
| Average | 28.46x | 6.67x | 19.95x | 2.02% | 418.36B | |
| Weighted average by Cap. | 35.66x | 8.54x | 21.85x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4527 Stock
- Valuation Rohto Pharmaceutical Co.,Ltd.
Select your edition
All financial news and data tailored to specific country editions
